Who Paid My Doc
David Beaton Comulada
Orthopaedic Surgery San Juan, PR Medical Doctor
NPI 1194176578 CMS profile 11555154
1785 Carr 21, Ste 202, San Juan, PR 00921
General payments
$28,854
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Beaton Comulada of San Juan, PR is reported in the CMS Open Payments database as having received $28,854 across 95 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 84th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,450 | 20 | |
| 2024 | General | $11,168 | 68 | |
| 2023 | General | $15,235 | 7 |
Beside peers
- David Beaton Comulada
- Orthopaedic Surgery median
- Middle half of Orthopaedic Surgery
- National median
In program year 2025, general payments to David Beaton Comulada were reported at $2,450. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.
Show as a table
| Year | David Beaton Comulada | Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $644 | $140–$2,844 | $163 |
| 2020 | $0 | $312 | $75–$1,860 | $114 |
| 2021 | $0 | $520 | $117–$2,495 | $132 |
| 2022 | $0 | $598 | $128–$2,731 | $149 |
| 2023 | $15,235 | $461 | $128–$2,264 | $160 |
| 2024 | $11,168 | $497 | $134–$2,475 | $164 |
| 2025 | $2,450 | $563 | $147–$2,717 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
31
Drug cost
$130
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 31 | $130 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Records
95 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery in Puerto Rico
Alberto Rivera Rosado
Orthopaedic Surgery · Santurce, PR
Andres Muniz Martinez
Orthopaedic Surgery · Cayey, PR
John Kagan
Orthopaedic Surgery · Humacao, PR
Juan Santiago Torres
Orthopaedic Surgery · Hatillo, PR
Ariel Davila-Parrilla
Orthopaedic Surgery · San Juan, PR
Francisco Lopez-Gonzalez
Orthopaedic Surgery · San Juan, PR
Related records
Orthopaedic Surgery in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.